Quest Diagnostics Inc (DGX) Holdings Reduced by Toth Financial Advisory Corp

Share on StockTwits

Toth Financial Advisory Corp lowered its holdings in Quest Diagnostics Inc (NYSE:DGX) by 17.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,038 shares of the medical research company’s stock after selling 8,740 shares during the quarter. Toth Financial Advisory Corp’s holdings in Quest Diagnostics were worth $3,690,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. raised its stake in shares of Quest Diagnostics by 32.7% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 544 shares of the medical research company’s stock worth $45,000 after buying an additional 134 shares during the last quarter. Moody National Bank Trust Division raised its stake in shares of Quest Diagnostics by 1.5% during the 4th quarter. Moody National Bank Trust Division now owns 12,082 shares of the medical research company’s stock worth $1,006,000 after buying an additional 182 shares during the last quarter. ETF Managers Group LLC raised its stake in shares of Quest Diagnostics by 17.7% during the 4th quarter. ETF Managers Group LLC now owns 1,322 shares of the medical research company’s stock worth $110,000 after buying an additional 199 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in shares of Quest Diagnostics by 1.6% during the 4th quarter. Pinnacle Associates Ltd. now owns 13,554 shares of the medical research company’s stock worth $1,129,000 after buying an additional 216 shares during the last quarter. Finally, Commonwealth Bank of Australia raised its stake in shares of Quest Diagnostics by 1.4% during the 4th quarter. Commonwealth Bank of Australia now owns 19,523 shares of the medical research company’s stock worth $1,620,000 after buying an additional 262 shares during the last quarter. 90.46% of the stock is owned by institutional investors.

DGX stock traded up $1.11 during trading on Monday, hitting $90.99. The stock had a trading volume of 591,240 shares, compared to its average volume of 1,270,655. Quest Diagnostics Inc has a 1-year low of $78.95 and a 1-year high of $116.49. The company has a market capitalization of $12.10 billion, a price-to-earnings ratio of 14.42, a PEG ratio of 2.10 and a beta of 0.90. The company has a current ratio of 0.94, a quick ratio of 0.87 and a debt-to-equity ratio of 0.65.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, February 14th. The medical research company reported $1.36 earnings per share for the quarter, missing the consensus estimate of $1.37 by ($0.01). Quest Diagnostics had a net margin of 9.77% and a return on equity of 15.23%. The firm had revenue of $1.84 billion during the quarter, compared to analyst estimates of $1.88 billion. During the same period in the previous year, the firm posted $1.40 EPS. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, research analysts predict that Quest Diagnostics Inc will post 6.46 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 22nd. Shareholders of record on Monday, April 8th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.33%. The ex-dividend date of this dividend is Friday, April 5th. Quest Diagnostics’s dividend payout ratio (DPR) is 33.60%.

Several research analysts have recently issued reports on the company. Zacks Investment Research downgraded Quest Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. Argus downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, January 31st. Piper Jaffray Companies cut their price target on Quest Diagnostics from $110.00 to $100.00 and set a “neutral” rating for the company in a research note on Thursday, February 14th. UBS Group set a $91.00 price target on Quest Diagnostics and gave the stock a “hold” rating in a research note on Friday, February 15th. Finally, Barclays reaffirmed a “buy” rating and set a $114.00 price target on shares of Quest Diagnostics in a research note on Friday, February 15th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. Quest Diagnostics presently has a consensus rating of “Hold” and an average price target of $102.50.

In other Quest Diagnostics news, SVP Everett Cunningham sold 1,496 shares of Quest Diagnostics stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $86.64, for a total value of $129,613.44. Following the completion of the sale, the senior vice president now owns 39,755 shares in the company, valued at approximately $3,444,373.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael E. Prevoznik sold 336 shares of Quest Diagnostics stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $88.23, for a total value of $29,645.28. Following the completion of the sale, the senior vice president now owns 42,108 shares of the company’s stock, valued at approximately $3,715,188.84. The disclosure for this sale can be found here. Insiders sold a total of 88,106 shares of company stock valued at $7,935,229 in the last 90 days. 1.79% of the stock is owned by company insiders.

WARNING: This report was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://weekherald.com/2019/04/15/quest-diagnostics-inc-dgx-holdings-reduced-by-toth-financial-advisory-corp.html.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

See Also: Systematic Risk

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.